Method of treating alvelor bone loss through the use of anti-sclerostin antibodies

A method for increasing alveolar bone height in a subject suffering from alveolar bone loss comprising administering to the subject an anti-sclerostin antibody in an amount effective to decrease the distance between the cement-enamel junction and the alveolar bone crest, at a dose from about 5 mg to about 1,000 mg per week, and wherein the anti-sclerostin antibody comprises a light chain variable region amino acid sequence set forth in SEQ ID NO:

• 376 and a heavy chain variable region amino acid sequence set forth in SEQ ID NO:
• 378.